SG/CALL/NOVO-NORDISK B/1180/0.1/21.03.25 | Real-time Boerse Frankfurt Warrants 13:31:52 03/06/2024 BST | ||
| 0.53 EUR | -3.64% |
|
| 1 month | -24.66% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 03/06/24 | 0.53 | -3.64% |
| 31/05/24 | 0.55 | +1.85% |
| 30/05/24 | 0.54 | +3.85% |
| 29/05/24 | 0.52 | -10.34% |
| 28/05/24 | 0.58 | -15.94% |
Real-time Boerse Frankfurt Warrants
Last update June 03, 2024 at 01:31 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SW7ZJG |
| ISIN | DE000SW7ZJG1 |
| Date issued | 20/03/2024 |
| Strike | 1,180 kr |
| Maturity | 21/03/2025 (291 Days) |
| Parity | 10 : 1 |
| Emission price | 0.91 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.92 € |
|---|---|
| Lowest since issue | 0.5 € |
| Spread | 0.01 € |
| Spread % | 1.85% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
927.3
DKK
Average target price
917.2
DKK
Spread / Average Target
-1.09%
- Stock Market
- Warrants
- Warrant
